Immutep’s Efti with Radiotherapy & KEYTRUDA^® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Immutep Limited announced the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa with radiotherapy plus KEYTRUDA^® in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint.